TY - JOUR
T1 - Risk of lung cancer in lung transplant recipients in the United States
AU - Triplette, Matthew
AU - Crothers, Kristina
AU - Mahale, Parag
AU - Yanik, Elizabeth L.
AU - Valapour, Maryam
AU - Lynch, Charles F.
AU - Schabath, Matthew B.
AU - Castenson, David
AU - Engels, Eric A.
N1 - Funding Information:
This research was supported in part by the Intramural Research Program of the National Cancer Institute. The authors gratefully acknowledge the support and assistance provided by individuals at the Health Resources and Services Administration (Monica Lin), the SRTR (Ajay Israni, Bertram Kasiske, Paul Newkirk, Jon Snyder), and the following cancer registries: the states of California (Tina Clarke), Colorado (Jack Finch), Connecticut (Lou Gonsalves), Florida (Brad Wohler), Georgia (Rana Bayakly), Hawaii (Brenda Hernandez), Iowa, Illinois (Lori Koch), Kentucky (Jaclyn Nee), Michigan (Glenn Copeland), New Jersey (Xiaoling Niu), New York (Amy Kahn), North Carolina (Chandrika Rao), Texas (Leticia Nogueria), and Utah (Janna Harrell), and the Seattle‐Puget Sound area of Washington (Margaret Madeleine). We also thank Kelly Yu at the National Cancer Institute for study management, and analysts at Information Management Services for programming support (David Castenson, Matthew Chaloux, Michael Curry, Ruth Parsons). The SRTR is currently operated under contract number HHSH250201500009C (Health Resources and Services Administration) by the Minneapolis Medical Research Foundation, Minneapolis, MN. Previously the SRTR was managed under contracts HHSH250201000018C and HHSH234200537009C. The following cancer registries were supported by the SEER Program of the National Cancer Institute: California (contracts HHSN261201000036C, HHSN261201000035C, and HHSN261201000034C), Connecticut (HHSN261201300019I), Hawaii (HHSN261201000037C, N01‐ PC‐35137, and N01‐PC‐35139), Iowa (HSN261201000032C and N01‐PC‐35143), New Jersey (HHSN261201300021I and N01‐ PC‐2013‐00021), Seattle‐Puget Sound (N01‐PC‐35142), and Utah (HHSN2612013000171). The following cancer registries were supported by the National Program of Cancer Registries of the Centers for Disease Control and Prevention: California (agreement 1U58 DP000807‐01), Colorado (U58 DP000848‐04), Georgia (5U58DP003875‐01), Illinois (5U58DP003883‐03), Maryland (U58DP12‐1205 3919‐03), Michigan (5U58DP003921‐03), New Jersey (NU58DP003931‐05‐00), New York (U58DP003879), North Carolina (U58DP003933), and Texas (5U58DP000824‐04). Additional support was provided by the states of California, Colorado, Connecticut, Illinois, Iowa, Massachusetts (Massachusetts Cancer Prevention and Control Cooperative Agreement 5458DP003920), New Jersey, New York (including the Cancer Surveillance Improvement Initiative), Texas, Utah, and Washington, as well as the University of Utah and Fred Hutchinson Cancer Research Center in Seattle, WA. The views expressed in this paper are those of the authors and should not be interpreted to reflect the views or policies of the National Cancer Institute, Health Resources and Services Administration, SRTR, cancer registries, or their contractors. Dr. Triplette was supported by a training grant from the NHLBI/NIH (T32 HL007287) during the conduct of this study.
Funding Information:
6Scientific Registry of Transplant Recipients, Minneapolis Medical Research Foundation, Minneapolis, Minnesota
Publisher Copyright:
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons
PY - 2019/5
Y1 - 2019/5
N2 - Lung transplant recipients have an increased risk of lung cancer that is poorly understood. Prior studies are largely descriptive and single-center, and have not examined risk factors or outcomes in this population. This registry-linkage study utilized matched transplant and cancer registry data from 17 US states/regions during 1987-2012. We used standardized incidence ratios (SIRs) to compare incidence with the general population, Poisson models to identify lung cancer risk factors, and Cox models to compare survival after diagnosis. Lung cancer risk was increased among lung recipients (SIR 4.8, 95% confidence interval [CI] 4.1-5.5). Those with single lung transplant had 13-fold (95% CI 11-15) increased risk in the native lung. Native lung cancer risk factors included age, prior smoking, time since transplant, and idiopathic pulmonary fibrosis. Compared with cases in the general population, lung cancers in recipients were more frequently localized stage (P =.02) and treated surgically (P =.05). However, recipients had higher all-cause (adjusted hazard ratio 1.90, 95% CI 1.52-2.37) and cancer-specific mortality (adjusted hazard ratio 1.67, 95% CI 1.28-2.18). In conclusion, lung cancer risk is increased after lung transplant, especially in the native lung of single lung recipients. Traditional risk factors are associated with lung cancer in these patients. Lung cancer survival is worse among lung recipients despite earlier diagnosis.
AB - Lung transplant recipients have an increased risk of lung cancer that is poorly understood. Prior studies are largely descriptive and single-center, and have not examined risk factors or outcomes in this population. This registry-linkage study utilized matched transplant and cancer registry data from 17 US states/regions during 1987-2012. We used standardized incidence ratios (SIRs) to compare incidence with the general population, Poisson models to identify lung cancer risk factors, and Cox models to compare survival after diagnosis. Lung cancer risk was increased among lung recipients (SIR 4.8, 95% confidence interval [CI] 4.1-5.5). Those with single lung transplant had 13-fold (95% CI 11-15) increased risk in the native lung. Native lung cancer risk factors included age, prior smoking, time since transplant, and idiopathic pulmonary fibrosis. Compared with cases in the general population, lung cancers in recipients were more frequently localized stage (P =.02) and treated surgically (P =.05). However, recipients had higher all-cause (adjusted hazard ratio 1.90, 95% CI 1.52-2.37) and cancer-specific mortality (adjusted hazard ratio 1.67, 95% CI 1.28-2.18). In conclusion, lung cancer risk is increased after lung transplant, especially in the native lung of single lung recipients. Traditional risk factors are associated with lung cancer in these patients. Lung cancer survival is worse among lung recipients despite earlier diagnosis.
KW - cancer/malignancy/neoplasia
KW - cancer/malignancy/neoplasia
KW - clinical research/practice
KW - epidemiology
KW - health services and outcomes research
KW - lung disease
KW - lung transplantation/pulmonology
KW - malignant
KW - registry/incidence
KW - risk factors
UR - http://www.scopus.com/inward/record.url?scp=85058675666&partnerID=8YFLogxK
U2 - 10.1111/ajt.15181
DO - 10.1111/ajt.15181
M3 - Article
C2 - 30565414
AN - SCOPUS:85058675666
VL - 19
SP - 1478
EP - 1490
JO - American Journal of Transplantation
JF - American Journal of Transplantation
SN - 1600-6135
IS - 5
ER -